Aktienanalyse zu Omnicell Inc (OMCL)OMCLOmnicell Inc

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions. It operates in the Healthcare sector (ELECTRONIC COMPUTERS industry).

Omnicell Inc. is currently priced at $35.39, which is below the average analyst price target of $55, indicating potential upside. The company's recent gross margin has improved to 48.98%, reflecting strong operational efficiency. However, the stock has experienced a year-to-date decline of 21.60%, which raises concerns about its near-term performance. Additionally, insider selling has increased by 151.38%, suggesting potential caution from insiders. Given these factors, it may be prudent to hold rather than buy at this time, awaiting clearer signals from upcoming earnings on October 29, 2026.

8 analysts cover OMCL: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 54.20.